Professional Background and Role at Novartis AG
Dr. Shahram Ebadollahi served as the Chief Data and AI Officer and Global Head of Data Science and AI at Novartis AG until his departure announcement on February 8, 2023. During his tenure, he was responsible for defining and shaping the global strategy for data science, advanced analytics, and artificial intelligence across the organization. His role centered on integrating AI and data-driven insights into the workflows of scientists and employees to accelerate drug discovery, clinical development, and innovation within Novartis.
Ebadollahi’s leadership was pivotal in Novartis’s transformation into a data science-driven company. He championed the adoption of AI-enabled platforms to shorten the traditionally long drug development cycles, enabling Novartis scientists to reduce breakthrough medicine development timelines from years to weeks or even days. Notably, he oversaw initiatives that aimed to embed AI tools throughout Novartis’ operations, extending AI accessibility to every employee as part of a digital culture shift, partnering extensively with key technology companies such as Microsoft to leverage cloud services for AI development.
He was directly involved in strategic partnerships and innovation hubs that functioned as Novartis’ engines for AI innovation, including driving projects for remote and digitally enabled clinical trials. This reflects his commitment to combining AI with digital solutions to improve both R&D efficiency and patient outcomes.
Career Highlights and Expertise
- Prior to joining Novartis, Ebadollahi had a distinguished career at IBM, where he pioneered healthcare research initiatives focused on applying AI and data science to biomedical domains. This foundation supported his executive leadership at Novartis in driving enterprise-wide AI strategies.
- Ebadollahi is recognized as a technology and business leader with over 30 years of experience in AI, data science, and healthcare innovation.
- His expertise includes pattern recognition, signal analysis, and medical video content analysis, underpinning his capability to translate complex data into actionable insights.
- Post-Novartis, he has taken on a role as an Operating Partner at a private equity firm, indicating a strategic shift towards investment and advisory roles in technology and healthcare sectors.
- He serves as an Independent Director at Enko, a company focused on precision agriculture leveraging AI, reflecting his broad AI application experience beyond pharmaceuticals.
Contributions and Industry Influence
- His work contributed significantly to Novartis’ ambition to become a fully data-driven organization, influencing operational excellence and clinical innovation.
- Ebadollahi participated in global forums and working groups on AI in healthcare, including contributions to the Artificial Intelligence in Health Care reports and collaborations with organizations such as the Novartis Foundation on leveraging AI to improve global population health.
- He helped establish Novartis’ AI residency programs and internal capability-building to sustain long-term AI advancements.
- He actively engaged in thought leadership by speaking at events like Intelligent Health UK and HLTH 2021, emphasizing the transformative impact of AI in healthcare research and clinical practice.
Educational and Professional Affiliations
- Dr. Ebadollahi is linked with Columbia Engineering, serving on leadership or advisory boards, reflecting a connection to academia and research communities.
- His academic credentials include a PhD and MBA, supporting his dual technical and managerial expertise.
Summary of actionable intelligence: Shahram Ebadollahi led Novartis’s enterprise-wide data science and AI strategy as Chief Data and AI Officer until early 2023, driving accelerated drug discovery and operational modernization through AI adoption. His deep experience in healthcare AI, strategic industry partnerships (notably with Microsoft), and digital innovation initiatives position him as a critical architect of Novartis’s AI transformation. His current role in private equity and board memberships signals continued influence in AI-driven health and tech sectors, making his legacy and network valuable for advanced data science, AI partnerships, and innovation collaborations.
